The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
Abstract
Interview with Dr. Roy Perlis on esketamine as an option for treatment-resistant depression. (08:16)Download The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset of effect against its abuse potential, which led to a Risk Evaluation and Mitigation Strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The symptoms may last months or even years [127, 128].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [127]
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Walker, E. R., McGee, R. E., & Druss, B. G. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2502 · Cited by 2,976
Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
Kavalali, E. T., & Monteggia, L. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040531 · Cited by 258
Treatment-resistant depression and suicidality
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256
Khin, N. A., Chen, Y., Yang, Y., Yang, P., & LAUGHREN, T. P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06191 · Cited by 211
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–333 of 333
Repurposed Drugs of Abuse (Stimulants, Ketamine, and Psychedelics): Focus on Risks
Souza‐Marques, B., Caliman‐Fontes, A. T., Leal, G. C.-G., Bandeira, I. D., Mello, R. P., Alves-Pereira, R., & Quarantini, L. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-85519-1_28
Investing in Group Psychedelic Therapy for Latinx Immigrants
Zambrano, J., Forcén, F. E., Hidalgo, J., & King, F. (2025) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-025-01702-0
Sun, Z., Jiang, L., Xing, Y., & Luo, F. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099793
Xie, H., Xie, M., Ma, W., Li, Q., & Li, T. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_2
Miner, J. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-68468-5_42
Rømer, T. B., Frederiksen, C. G., Hansen, P. B., Christensen, R. H. B., & Benros, M. E. (2025) · Trials · doi:10.1186/s13063-025-08989-2
Esketamina, el novedoso antidepresivo intranasal para los casos resistentes
Lopez-Munoz, F. J., & Guirao, J. (2022) · doi:10.64628/aao.xx5rejtjx
Glutamatergic Changes Induced by Stress in the Brain and Effects of Rapid-Acting Antidepressants
Mingardi, J., & Musazzi, L. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_35
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19136042
Liu, C.-Y., Chen, J., Liu, Y., Zhou, X.-M., Zhang, M., Jiang, Y.-M., Ma, Q.-Y., Xue, Z., Zhao, Z.-Y., Li, X.-J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19863026
Ketamine as a prophylactic agent against post-traumatic stress disorder
Peavey, J. (2023) · Journal of High School Science · doi:10.64336/001c.87422
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19136048
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19136045
Li, Y.-Z., Zhao, C.-Q., Zuo, M.-Y., Wang, R.-G., Williams, J. P., & An, J.-M. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121311 · Cited by 1
McNaughton, N., Shadli, S. M., Beaglehole, B., & Glue, P. (2026) · Journal of the Royal Society of New Zealand · doi:10.1002/snz2.70002
Inserra, A., VanderZwaag, J., Campanale, A., Murray, C. J., & Szabo, A. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27340-7.00008-5
Dumaresq, M. C. H., Filho, G. D. D., Dumaresq, D. M. H., Patrocínio, M. C. A., & Verde, L. G. S. L. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n3-008
Wasolua, T. T., Bommersbach, T. J., McIntyre, R. S., & Rhee, T. G. (2026) · Research Square · doi:10.21203/rs.3.rs-9827580/v1
Zhang, B., Wang, Z., Yu, K., Pan, Q., Guan, S., Zhang, M., Jia, R., Wang, Y., Meng, Q., Ma, Y., et al. (2026) · Perioperative Medicine · doi:10.1186/s13741-026-00711-3
Glue, P., & Beaglehole, B. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70225
Chang, C.-H., Hsia, Y.-D., Liu, W.-C., Lin, C., Ying, J., & Tsai, H.-C. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1837402
Chen, Z., Wang, Y., Cong, P., Wang, L., Sun, P., Li, Z. Y., Zhang, H., Li, G., Jiao, F., Zhao, J., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2692804
Wang, Y., Zhou, L., Xu, R., Yang, N., Kuang, R., Li, L., & Peng, L. (2026) · BMC Anesthesiology · doi:10.1186/s12871-026-04042-0
Lv, Y., Yang, Z., Li, L., Xu, Y., Qin, Y., Deng, B., & ZHAI, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179153
Giovenzana, M., Nicosia, N., Spinosa, S., Musazzi, L., & Mingardi, J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108366
Propofol for depression: mechanisms and therapeutic potential
Yu, D., Liao, Y., Li, J., Zheng, A., Meng, X., Gong, S., Li, C., & Kunwei, W. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1876988
Kim, T. H., & Nam, B. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_17
Schwartz, E. R., Sabbag, S. A., Buford, U., Kieffer, L., & Allespach, H. H. (2026) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_33-4
Tuberostemonine produces antidepressant effects via the BDNF/TrkB/Erk/CREB signaling pathway
Chen, F., Li, L., Xu, X., Meng, Z., Yu, Q., Chen, L., Ai, Q., Deng, Y., Wei, J., Liang, G., et al. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.118064
Navigating the Complexities of Treatment-Resistant Depression in Late Life
Cross, C. B., Hristidis, V. C., & Lenze, E. J. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20260010
Mathai, D. S., Pilecki, B. C., Zaki, H., Morris, T., Morris, M., & Garcia‐Romeu, A. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100046
Metadata
- Authors
- Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R.
- Affiliations
- United States Food and Drug Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-04
- Volume
- 381
- Issue
- 1
- Pages
- 1-4
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2946133992
- Cited by
- 333
- References
- 5
- Citations by year
- 2026: 26 · 2025: 47 · 2024: 56 · 2023: 37 · 2022: 55 · 2021: 51 · 2020: 48 · 2019: 13
- FWCI
- 25.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, treatment-resistant depression, FDA drug approval, NMDA receptor antagonists, antidepressants, abuse liability, risk evaluation and mitigation strategy
- MeSH terms
- Antidepressive Agents, Humans, Ketamine, United States, United States Food and Drug Administration, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
